The acute cardiovascular effects of a new xanthine, enprofylline, were studied in patients with chronic lung disease. The studies were done during cardiac catheterization (n = 12) and by radionuclide ventriculography (n = 6). Enprofylline was given intravenously, 2 mg/kg, and measurements were done after ten and 30 min. Enprofylline reduced the mnean pulmonary artery pressure from 30 ± 10 to 26 7 mm Hg (p<0.05) and the mean systemic arterial pressure from 92±17 to 83±15 mm Hg (p<O.Ol), increased the 7 Enprofylline is a new xanthine bronchodilator with a short half-life9 and which appears to be about five times as potent as theophylline in animals'0 and asthmatic patients."",2 Based on animal studies, enprofylline seems to have a more favorable pharmacologic profile with excretion of unmetabolized drug to the urine,9 and it seems to lack some of the extrapulmonary effects of theophylline like diuretic and central nervous system stimulant effects.5 The cardiovascular effects of enprofylline in man so far have been evaluated little, but studies are consistent with a positive inotropic and chronotropic effect of the drug. 1314 In this study, we examined the cardiovascular effects of a single intravenous dose of enprofylline in patients with severe chronic lung diseases. The studies included right heart catheterization and radionuclide ventriculography of right and left ventricles. Since a chronotropic effect of enprofylline has been reported,14 we also compared the hemodynamics after drug admin- 
The development of cor pulmonale with pulmonary hypertension and right ventricular failure are well known complications of chronic lung diseases and are i .~~~~~~, associated with a poor prognosis."2 Xanthines are widely used bronchodilators in these patients with cor pulmonale. However, drugs like theophylline which are metabolized in the liver, might have unpredictable half-lives in patients with heart failure.3'4 Furthermore, due to the adenosine-blocking effects of theophylline,5'6 the pharmacologic profile of the drug may be different in hypoxic situations with high adenosine production. 7 Enprofylline is a new xanthine bronchodilator with a short half-life9 and which appears to be about five times as potent as theophylline in animals'0 and asthmatic patients."",2 Based on animal studies, enprofylline seems to have a more favorable pharmacologic profile with excretion of unmetabolized drug to the urine, 9 and it seems to lack some of the extrapulmonary effects of theophylline like diuretic and central nervous system stimulant effects. 5 The cardiovascular effects of enprofylline in man so far have been evaluated little, but studies are consistent with a positive inotropic and chronotropic effect of the drug. 1314 In this study, we examined the cardiovascular effects of a single intravenous dose of enprofylline in patients with severe chronic lung diseases. The studies included right heart catheterization and radionuclide ventriculography of right and left ventricles. Since a chronotropic effect of enprofylline has been reported,14 we also compared the hemodynamics after drug admin- istration with hemodynamics before drug administration and increased heart rate induced by atrial pacing. The influence of enprofylline on arterial blood oxygenation and oxygen delivery were additionally addressed since some vasodilators in the pulmonary circulation have been shown to worsen the arterial blood oxygenation in patients with perfusion/ventilation imbalance. 15, 16 
METHODS

Patients
Eighteen patients with severe chronic lung disease were included in the study They were ten men and eight women of an average age of 66 years (range, 36 to 81 years). None of the patients had clinical or electrocardiographic evidence of coronary or valvular heart disease, systemic hypertension or primary myocardial disease. The criteria for inclusion in the study were (1) chronic lung disease in stable condition; (2) no clinical evidence ofleft-sided heart failure; (3) mean pulmonary capillary wedge pressure <12 mm Hg at rest; and (4) mean pulmonary artery pressure >16 mm Hg at rest. The patients were allowed to take digitalis, diuretics and bronchodilator spray, but all other cardiovascular drugs were discontinued 12 to 24 hs before each study The studies were performed after an overnight fast without premedication. Informed consent was obtained from all patients, and no complications resulted from the study The 12 patients receiving enprofylline (enprofylline group) and six patients receiving saline solution (control group). After the first six patients had received enprofylline, the following 12 patients were randomly assigned to receive either saline solution or enprofylline. The measurements were done with subjects in the supine position at rest, and 10 and 30 min following infusion of enprofylline or saline solution. Patients receiving enprofylline had an additional recording before drug infusion during atrial pacing at a heart rate about 10 beats per minute above resting heart rate. Radionuclide ventriculography was performed in six patients in the enprofylline group with measurements done before, and 10 and 30 min after drug administration.
Enprofylline Infusion
Enprofylline was given in a dose of 2 mg/kg intravenously as a slow infusion during 10 min. Femoral artery pressure was recorded continuously during drug infusion.
Statistical Analysis
Each patient served as his or her own control. Comparisons of differences in the results from before and after drug administration within each patient were done using the Wilcoxon test (two-tailed) for paired data and between enprofylline and control groups using Wilcoxon test for unpaired data (two-tailed). Linear regression analysis was used to determine the relationship between the blood pressure values before and the change after drug administration. 17 To avoid the problem of arbitrary regression to the mean, significant results were also analyzed by relating the change in values to the average of values before and after drug administration. 18 A probability value of <0.05 was regarded as statistically significant. All data are expressed as mean values ± 1 standard deviation.
RESULTS
Patient Characteristics
All patients had chronic lung diseases with severely impaired lung function with FVC 1.6+±0.9 L (mean ± SD) and FEV1 0.8±+0.5 L ( Fig 1) . Cardiac index was not significantly changed by the drug while stroke volume fell by 11 percent (p<0.05) and 13 percent (p<0.01) after 10 and 30 min, respectively A small reduction of the elevated mean pulmonary artery pressure was seen after enprofylline by an average of 10 percent (p<0.05) and 13 percent (p<0.01), but pulmonary vascular resistance was not significantly changed ( Fig  2) . The mean arterial pressure was reduced by 7 percent (p<0.05) and 10 percent (p<0.01) (Fig 2) (Fig 3) . When the change in pressure was related to the average value before and after enprofylline, the correlation was still significant (r = 0. 76, n = 12, p<0.01). No significant correlation was established between mean systemic arterial pressure before and the change in pressure after drug administration (r=0.41, n=12, NS).
When the cardiovascular changes during enprofylline administration were compared with values obtained during atrial pacing, no significant change in cardiac index or stroke volume was found (Fig 1) . However, enprofylline induced a significant reduction in mean pulmonary artery pressure, mean arterial pressure and in right ventricular stroke work index when compared with values during atrial pacing before drug administration (Fig 1 and 2) . In the control group no significant cardiovascular changes were found in the observation period ( Table 2) . Comparison changes found in the control group and enprofyllinetreated patients revealed significant changes after 30 min in heart rate, stroke volume, right ventricular stroke work index ( Table 2 , Fig 1) , and mean pulmonary artery pressure (Fig 2) .
Radionuclide Ejection Fraction Right ventricular ejection fraction was 39 + 5 percent in the control state and was abnormal (<45 percent) in five of the six patients. Enprofylline infusion did not significantly change the ejection fraction after either 10 min (42 + 8 percent) or 30 min (42 + 8 percent). The LV ejection fraction was 62 ± 8 percent before and did not change 10 min (65 + 9 percent) or 30 min (62 + 6 percent) after enprofylline infusion.
Effects on Blood Gases
No changes were observed in arterial or mixed venous blood gases or in systemic oxygen delivery Side Effects
Two patients experienced side effects. Both complained of nausea starting 10 and 20 min after start of drug infusion. The first patient also had mild epigastric discomfort and vomiting, which lasted two to three hs, while the second patient had nausea lasting for about 10 min.
DISCUSSION
The role ofxanthines in the treatment of obstructive lung diseases is a matter of dispute, mainly due to the narrow therapeutic window observed by the use of theophylline. In the patients with chronic lung diseases and cor pulmonale, serious cardiac side effects of these drugs have been reported.5"19'20 These cardiotoxic effects might be due to unpredictable high plasma concentrations of the drug in patients with heart failure, but might also be related to the adenosine blocking properties of theophylline.56
This study demonstrates a bronchodilating effect of enprofylline in seriously ill patients with chronic lung diseases and hypoxemia. The bronchodilating effect of enprofylline has been reported previously in patients with bronchial asthma9"0 and recently also in patients with moderate chronic obstructive lung disease. There was, however, no correlation between the improvement in lung function and the hemodynamic changes, indicating that different mechanisms might be responsible for the ventilatory and circulatory effects.
The infusion of enprofylline in this study induced a modest tachycardia and reduction of blood pressure in both systemic and pulmonary circulation. The fall in pulmonary artery pressure during enprofylline therapy could be due to an active dilation or recruitment of pulmonary vessels, or could be secondary to an improvement in ventilation or gas distribution. A direct vasodilating effect of enprofylline on the pulmonary vessels seems to be more likely than recruitment of vessels since the cardiac output and the pulmonary flow were unchanged. The reduction of pulmonary pressure was most pronounced in those patients with highest pulmonary artery pressure before drug infusion, suggesting that an active vasoconstriction is an important factor in the development of pulmonary hypertension in these patients. Also for other vasodilating agents in the pulmonary circulation like hydralazine, a close association between the degree of pulmonary blood pressure reduction and the pretreatment value has been reported.2223
Enprofylline has been reported to increase left ventricular contractility as determined by increased force of contraction in isolated guinea-pig left atria in a dose-dependent manner. 13 Using systolic time intervals in normal individuals, enprofylline was reported to have a positive inotropic effect at plasma concentrations exceeding 2 mg/L. '4 The results obtained in this study, however, are not consistent with any positive inotropic effect of enprofylline. First, the radionuclide study showed unchanged ejection fractions of right and left ventricles after enprofylline. Second, the stroke volume at constant heart rate was not improved by enprofylline in spite of the lowering of blood pressure in both systemic and pulmonary circulation with consequent reduction of biventricular afterload.
The cardiovascular response to enprofylline infusion in this study appears to differ somewhat from that observed by theophylline. Although the hemodynamic profile with tachycardia and reduction of blood pressure are similiar for the two drugs, the reduction in pulmonary vascular resistance seems, from reports in the literature, to be more prominent for theophylline.24.25 A comparison of the cardiovascular effects of theophylline and enprofylline should, however, be conducted in a randomly designed trial. This is consistent with the hypothesis that adenosine may be a potent pulmonary vasoconstrictor. 7, 26 Also the lack of increase in contractile function after enprofylline is in contrast to the findings by use of theophylline in therapeutic concentration.2728 Although the exact intracellular mechanism for the bronchial and cardiovascular effects of xanthines are largely unknown, it has been attributed to their phosphodiesterase inhibitory activity 29 alteration of calcium flux30 and release of catecholamines. 31 Additionally, at therapeutic concentrations theophylline has an inhibitory effect on adenosine receptors which is not shared by enprofylline.5 '6 Adenosine increases coronary flow and has a cardiodepressive effect which reduces the myocardial metabolic demand.26 In situations with limited oxygen supply, adenosine protects the ischemic myocardium from development of necrosis.32 Adenosine may have a protective effect on the heart under stress conditions like myocardial ischemia or during beta-adrenergic stimulation,26 which are potent stimuli for increased endogenous production of adenosine. It has been suggested that the cardiotoxic effect of theophylline might be explained by its adenosine blocking action, and enprofylline might thus have therapeutic advantages. In this study we did not observe any serious side effect of enprofylline. The transient nausea experienced in two patients was at the time of maximal serum concentrations. Harmful systemic hypotension, a potentially deleterious effect of vasodilators when used in patients with cor pulmonale and right ventricular dysfunction, did not occur in our patients. Some vasodilators which affect pulmonary vasculature have been shown to change arterial blood oxygenation with lowering of PaO215,6 due to worsening of the ventilation/perfusion mismatching in these patients. Lowering of PaO2 in hypoxemic patients has also been reported after use of xanthines. In this acute study, however, we could not demonstrate any fall in PaO2 after enprofylline.
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